Full Press Release Details
Independent Study Validates IceCure's
ProSense Cryoablation is Safe & Effective Outpatient
Procedure for Breast Cancer with
Israel, October 2, 2023 -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure" or the "Company"), developer of
the ProSense System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical
tumor removal, today announced that new data was presented at the European Society of Breast Imaging ("EUSOBI") Scientific
Meeting in Valencia, Spain by Luc a Gra a-L pez, MD, PhD, principal investigator of the independent, non-sponsored
In a poster titled "Cryoablation for the
treatment of early-stage breast cancer in patients who decline surgery" Dr. Gra a-L pez presented the findings of
her study conducted at University Hospital Lucus Augusti in Lugo, Spain which used ProSense for cryoablation treatment of 31 patients
with early-stage breast cancer who declined surgery, the standard of care. Dr. Gra a-L pez, a radiologist who specializes
in breast and women's imaging, is Head of the Breast Unit at University Hospital Lucus Augusti.
All patients were diagnosed with biopsy-proven
early breast cancer (cT1-2cN0-1cM0) with a median tumor size of 24 mm, ranging between 6 to 45 mm. Patients were followed by mammography
and ultrasound every 6 months for 2 years and annually thereafter. The median follow-up was 10 months, with a range of 0 to 40 months.
Cancer progression was observed in 1 patient (1/31, 3.2%). No major complications were seen and the procedure was well tolerated by all
The study concluded that cryoablation could be
an alternative treatment to surgery for breast cancer in patients who reject surgery. Underscoring the need for such an alternative, the
poster presented that breast cancer is the most commonly diagnosed malignant neoplasm worldwide and that while surgery is the standard
of care for early-stage breast cancer, some patients, most of them elderly, decline standard of care surgery and prefer a less invasive
Dr. Gra a-L pez commented, "I've
been effectively using ProSense for cryoablation in women who decline surgery with very good results. I think that soon, cryoablation
will be a real alternative to surgery in early-stage breast cancer in post-menopausal women. Beyond breast cancer, I believe ProSense
can have an impact on the way cancers of the kidney, lung, and thyroid gland are treated."
"Doctors around the world are using ProSense
with women who want an alternative to surgery for early- stage breast cancer, and it's highly encouraging to see these physicians
publish and share their results with the medical community," stated IceCure's CEO, Eyal Shamir. "These data are very
much in line with the interim results of our ICE3 study, the largest of its kind in the U.S., which is expected to conclude in the first
IceCure Medical (Nasdaq: ICCM)
develops and markets ProSense , an advanced liquid-nitrogen-based cryoablation therapy for the treatment of tumors (benign and cancerous)
by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. Its minimally invasive technology is a safe and
effective alternative to hospital surgical tumor removal that is easily performed in a relatively short procedure. The system is marketed
and sold worldwide for the indications cleared and approved to date including in the U.S., Europe, and China.
This press release contains forward-looking
statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and
other Federal and Israeli securities laws. Words such as "expects," "anticipates," "intends," "plans,"
"believes," "seeks," "estimates" and similar expressions or variations of such words are intended
to identify forward-looking statements. For example, IceCure is using forward looking statement in this press release when it discusses:
the expected conclusion of its ICE3 study in the first quarter of 2024; and that, according to Dr. Gra a-L pez, soon cryoablation
will be a real alternative to surgery in early-stage breast cancer in post-menopausal women. Historic
results of scientific research and clinical and preclinical trials do not guarantee that the conclusions of future research or trials
will suggest identical or even similar conclusions. Because such statements deal with future events and are based on IceCure's
current expectations, they are subject to various risks and uncertainties and actual results, performance, or achievements of IceCure
could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained
or implied in this press release are subject to other risks and uncertainties, many of which are beyond the control of the Company, including
those set forth in the Risk Factors section of the Company's Annual Report on Form 20-F for the year ended December 31, 2022 filed with
the SEC on March 29, 2023, and other documents filed with or furnished to the SEC which are available on the SEC's website, www.sec.gov.
The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required